Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.
The company experienced fourth quarter sequential and year-on-year revenue growth of 16%, driven by increased demand for drug testing cartridges.
Fiscal 2025 was a year of growth marked by higher-margin cartridge sales, operational streamlining, and regulatory advancements supporting future expansion in the U.S. market.
Revenue Growth
16% revenue growth in the fourth quarter compared to the previous year.
Operational Efficiency
Focus on operational streamlining to support future expansion plans.
Regulatory Advancements
Advancing efforts to secure U.S. FDA 510(k) clearance for market expansion.
International Expansion
Active customer base exceeding 450 accounts across 24 countries and 18 distribution partners.
Strategic Priorities for Fiscal 2026
Accelerating growth, advancing operational excellence, and expanding into the U.S. drug screening market.
- Fiscal 2025 marked significant progress towards the company's goal of expanding into the U.S. market beyond Forensic Use Only settings.
- Increased revenue, operational efficiencies, and regulatory advancements position Intelligent Bio Solutions for continued growth and market penetration.
- The focus on international expansion reflects the company's commitment to global presence and customer base growth.
With a successful fiscal year in 2025, Intelligent Bio Solutions is well-positioned to achieve further growth and expand its market presence in the coming year.